echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The first cancer electric field therapy Chinese real-world data from the group

    The first cancer electric field therapy Chinese real-world data from the group

    • Last Update: 2020-12-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    BEIJING, Sept. 13 (Xinhua Li Yanan) A forward-looking, one-arm observational study evaluating the treatment of tumor electric field in patients with glioblastoma (GBM) in China was recently presented at the 4th Annual Meeting and 4th China Cerebral Glioma Academic Conference of the Chinese Physicians Association's Brain Glioma Professional
    Conference. For the first time, the study published data on the efficacy of tumor electric field therapy Chinese in real-world cancer groups.
    glioblastoma is the most common and invasive adult brain tumor with the highest mortality rate other than pancreatic cancer. As the most common malignant tumor of the nervous system, the disease of glioblastoma progresses very quickly and is very easy to recur, the recurrence rate of patients is as high as 100%, the five-year survival rate is less than 5%, is considered to be one of the most difficult and difficult tumors in neurosurgery treatment. In August 2019, Epdon was awarded the "Innovative Medical Device Qualification", becoming the first innovative therapy approved for glioblastoma in Chinese mainland in 15 years.
    real-world study, co-sponsored by Chinese mainland and china
    , is the first study of cancer electric field therapy in a Chinese group. The study included 44 Chinese mainland patients in the
    Anjian Cancer Treatment Center, including 29 in the new GBM patient group and 15 in the relapsed GBM patient group.The results of the interim analysis of
    study showed that the medium progression-free survival of the new patients was 6.4 months, the medium total survival period had not yet been reached, the medium non-progression survival of the relapsed patients reached 4.5 months and the medium total survival period was 8.6 months, and the most common adverse reactions in terms of safety were mild to moderate skin irritation, all of which were grade I-II.
    "As the first real-world study of tumor electric field therapy in group Chinese, the safety and effectiveness of cancer electroneous field therapy in Chinese patients has been validated in stages," said Professor Jiang Tao, deputy director of the Beijing Institute of Neurosurgery, founder and founder of the China Cerebral Glioma Genome Map Database and founder of Tiantan Hospital in Beijing. In contrast to traditional therapies, side effects are concentrated in mild controlled adverse skin reactions. Therefore, this real-world research can be said to be for the clinical treatment of glioblastoma in China injected a strong heart agent. Next we will continue to follow up and look further at the long-term data. In
    2019, the State Drug Administration released the China Drug Regulatory Science Action Plan, which lists "methodological research on the use of real-world data for clinical evaluation of medical devices" as one of the first research projects to assist in drug and medical device research and development and regulatory decision-making.
    Professor Zhang Wei, Director of Neurosurgery, Tiantan Hospital, Beijing, said: "In order to provide patients with safer and more effective innovative treatment options, objectively evaluate the use of treatment options in the actual clinical situation, support the state's regulatory decision in the field of medical devices, since last year's oncology electric field treatment in
    , we immediately began to carry out research with
    Anjian Cancer Treatment Center on cancer electrostational therapy in the real world." The study, which began last June, is the first to date based on the treatment of tumor electric field in Chinese patients, filling the data gap in the treatment of tumor electric field in patients with glioblastoma in China and providing clinicians with more evidence-based evidence in choosing innovative treatment options. " (Complete)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.